FORT WORTH, Texas, April 12, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced that the Company has signed a multi-year agreement with Omni Medical Products of McAllen, Texas to distribute CellerateRX® gel products in select states in the southwestern U.S. To maintain the distributorship, the agreement calls for 1st year sales of at least $650,000 and additional sales each subsequent year.
According to Deborah Jenkins Hutchinson, President of Wound Management Technologies, "We are pleased to have Omni Medical Products distributing Wound Management's gel products in select states. This agreement is part of our broader campaign to establish CellerateRX® as the standard of care in wound treatment."
Ron Mathis, Senior VP of Sales stated, "I am optimistic that as our sales increase we will continue to find broad distribution channels for the product. This new relationship along with our recent television campaigns should help to provide the exposure necessary to grow the company."
Scott Haire, WNDM CEO was quoted, "It is exciting to watch as our revenues continue to grow, partnerships like this with Omni along with the recent announcement of our Middle East orders are all very encouraging signs that we will achieve meeting our 2011 revenue projections."
For additional news and information concerning the CellerateRX® line of wound care products, please visit Wound Management Technology's newly re-launched product website www.CellerateRX.com.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA clear
|SOURCE Wound Management Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved